OBJECTIVES Cerebral vasospasm remains the leading cause of death and permanent disability after subarachnoid haemorrhage. This study determined whether the method of aneurysm treatment plays an important role in determining the incidence of cerebral vasospasm and its clinical consequences. METHODS Admission data, cranial computed tomography (CT), treatment details, transcranial Doppler (TCD) ...

BACKGROUND AND PURPOSE Subarachnoid hemorrhage (SAH) is a relatively rare cause of stroke with a high rate of morbidity and mortality, primarily due to the occurrence of delayed vasospasm. To date, many therapies have been proposed to help prevent vasospasm, but very few have been proven effective. The initiation of statin therapy after SAH may be effective in reducing the incidence of vasospas...

BACKGROUND AND PURPOSE The effects of aneurysm treatment modality (clipping or coiling) on the incidence of cerebral vasospasm and infarction after subarachnoid hemorrhage have not been clearly defined. We hypothesized that there may be a difference in angiographic and clinical vasospasm, cerebral infarction, and clinical outcome between patients undergoing clipping compared to coiling. METHO...

Introduction Subarachnoid hemorrhage-induced vasospasm is a well-recognized complication of aneurysm rupture and accounts for significant morbidity and mortality. The development and severity of vasospasm seems to be related to the amount of blood surrounding the vessel and the duration of exposure, indicating that some erythrocyte component, most likely hemoglobin, is ultimately responsible fo...

Cerebral vasospasm following aneurysmal subarachnoid hemorrhage is one of the most important causes of cerebral ischemia, and is the leading cause of death and disability after aneurysm rupture. There are two definitions of cerebral vasospasm: angiographic and clinical. Care must be exercised to be certain that it is clear which entity is being addressed. The diagnosis of the clinical syndrome ...

Background: Cerebral vasospasm and delayed cerebral ischemia continue to be major contributors to morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). Purpose: The purpose of this review was to evaluate the pharmacotherapy interventions for the prevention and management of cerebral vasospasm in patients with SAH. Methods: A search of MEDLINE (January 1966-April 2012) and EMBA...

BACKGROUND Cerebral infarction after aneurysmal subarachnoid haemorrhage (SAH) is presumed to be due to cerebral vasospasm, defined as arterial lumen narrowing from days 3 to 14. METHODS We reviewed the computed tomography scans of 103 patients with aneurysmal SAH for radiographic cerebral infarction and controlled for other predictors of outcome. A blinded neuroradiologist reviewed the angio...

BACKGROUND AND PURPOSE This randomized, double-blind, placebo-controlled, dose-finding study assessed efficacy and safety of 1, 5, and 15 mg/h intravenous clazosentan, an endothelin receptor antagonist, in preventing vasospasm after aneurysmal subarachnoid hemorrhage. METHODS Patients (n=413) were randomized to placebo or clazosentan beginning within 56 hours and continued up to 14 days after...

Cerebral vasospasm is a well-known entity following aneurysmal subarachnoid hemorrhage. While it has been described in trauma, much less studied. There have no previous reports of cerebral spontaneous subdural hematoma or after evacuation. In this case report, we present 38-year-old otherwise healthy female who suffered an acute hematoma. After surgical evacuation her hematoma, she developed ne...

Abstract Background Diffuse coronary artery spasm after bypass grafting may cause disastrous circulatory collapse and death if not detected managed promptly. Case presentation Four out of 387 patients who underwent uneventful off-pump between January 2019 December 2021 at our centre developed unexplained arrhythmias hypotension within 2 to 6 h the postoperative period. Coronary angiogram showed...